

EndomeTRIO Manual

A complete view of the endometrial health

Summary

ERA – Endometrial Receptivity Analysis - 4

Rationale - 5

Indications for ERA - 6

Methodology -7

Interpretation of the results - 9

ERA example report – 11

Reproducibility of the test - 12

ERA Decision Tree - 13

References - 14

EMMA – Endometrial Microbiome Metagenomic Analysis - 17

Rationale - 18

Indications for EMMA - 19

Methodology - 19

EMMA sample report- 20

Benefits of molecular analysis of the microbiota vs *microbial culture* – 25

EMMA decision tree - 26

References – 27

ALICE – Analysis of Infectious Chronic Endometritis - 29

Rationale - 30

Indications for ALICE - 30

Methodology - 31

ALICE report - 32

Benefits of molecular analysis of the microbiota vs histology, hysteroscopy and *microbial culture*– 34

ALICE decisión tree - 35

References- 36

Endometrial biopsy - 37

Requirements for taking an endometrial biopsy - 38

Day of endometrial biopsy for ERA alone or coupled with EMMA/ALICE – 39

HRT routine protocol – 40

Natural cycle: routine protocol - 42

Day of Endometrial Biopsy for EMMA and/or ALICE (without ERA) – 43

Day of Endometrial Biopsy: Summary Table – 44

Day of Endometrial Biopsy: invalid protocols - 45

Endometrial Biopsy Protocol - 46

Logistics – 48

A complete view of endometrial health – 49

List of abbreviations - 50

ERA[®]

Endometrial Receptivity Analysis

Rationale

The endometrial factor plays a key role in embryo implantation. In addition to evaluating malformations or anomalies in the uterine cavity, it is also important to determine when the endometrium is receptive, i.e., when the window of implantation (WOI) begins. Recurrent implantation failure (RIF) patients may have a displaced window of implantation, leading to embryo transfer into a non-receptive endometrium (Ruiz-Alonso et al. Fertil Steril, 2013).

The endometrial gene expression signature allows evaluation of endometrial receptivity, identifying a personalized window of implantation for each patient.

This analysis is carried out by a tool designed, developed and patented in 2009 (PCT/ES2009/000386) by Igenomix, after more than 10 years of research (Diaz-Gimeno et al. Fertil Steril, 2011; 2013) to identify the window of implantation in the endometrial cycle, enabling personalized embryo transfer (pET).

Research by Igenomix has demonstrated that synchronization between an implantation-ready embryo and a receptive endometrium increases the chances of success in an assisted reproductive treatment (Ruiz-Alonso et al. Fertil Steril, 2013; Ruiz-Alonso et al. Hum Reprod, 2014; Clemente-Ciscar et al. Hum Reprod, 2018; Simon et al. Reprod BioMed Online, 2020).

Other groups have also published similar results from their own patients after guided embryo transfer according to ERA results (Mahajan J Hum Reprod, 2015; Hashimoto et al. Reprod Med Biol, 2017; Findikli et al. Hum Reprod, 2018; Pasternak et al. Fertil Steril, 2018; Taguchi et al. Fertil Steril, 2018; Jia et al. Med Sci Monit, 2022).

ERA (Endometrial Receptivity Analysis), determines the optimal time in the endometrial cycle to perform embryo transfer. Thus, ERA can increase the chances of pregnancy by synchronizing an implantation-ready embryo with a receptive endometrium.

Indications for ERA

ERA is indicated for **patients with recurrent implantation failure (RIF)**, since they are at higher risk of having a displaced window of implantation (Ruiz-Alonso et al. Fertil Steril, 2013). On the other hand, the application of ERA to patients without RIF has also been explored (Simon et al. Reprod BioMed Online, 2020).

Our studies have shown there are other circumstances in which patients are at higher risk of having a displaced WOI. In these cases, ERA could help to find the optimal moment for the embryo transfer:

- Patients with **BMI > 30** (Comstock et al, 2017; Bellver et al, 2021)
- Patients with **endometrial atrophy** (endometrial thickness < 6 mm) (Valbuena et al, 2016)
- Patients with **adenomyosis** (Mahajan et al, 2018)
- Patients with **recurrent biochemical pregnancies** (Diaz-Gimeno et al, 2017)

Methodology

This test uses **Next Generation Sequencing (NGS) technology to analyze the expression of 248 genes related to endometrial receptivity status.**

The results from this test are based on the expression analysis of these 248 genes with a computational predictor designed and developed by Igenomix. After sequencing the genetic material (RNA) from an endometrial biopsy, it is possible to evaluate if the endometrium is Receptive or Non-receptive at any specific time during the endometrial cycle. **This result will be coupled to a recommendation for personalized embryo transfer according to each patient's specific endometrial profile.** In 10% of cases, it may be necessary to validate the personalized window of implantation by performing a second endometrial biopsy on the specific day designated by the first ERA test.

To enable reproducibility of results, the ERA test must be performed under identical conditions as the subsequent embryo transfer cycle (cycle type, treatment, method of administration...), **and always during a hormone replacement therapy (HRT) or natural cycle.** This test cannot be performed in controlled ovarian stimulated cycles.

For certain subsequent ERA mock cycles, to finalize diagnostics, our team may contact you to collect information about the patient's mock cycle. This is to understand if the protocols were replicated exactly in order to know if the results from the cycles can be correlated or not. **Correlation of the results helps our diagnostic team to review both results and provide a more personalized recommendation,** for example in the case of a narrow WOI. Without confirming this information and considering correlation, we may be missing a special observation that requires a more personalized recommendation for transfer, beyond what is provided by our algorithm.

The **first endometrial biopsy should be taken after 5 full days with progesterone administration (P+5) in an HRT cycle (120 hours with progesterone administration). In Natural cycles, the first endometrial biopsy should be taken 7 days (168 hours) after the hCG triggering (hCG+7) or after the LH peak (LH+7). It could be also taken 6 days after ovulation confirmed by ultrasound** (although this last option is not optimal because it is difficult to ensure reproducibility of the results).

If day-3 embryos are to be transferred, the biopsy should be performed at P+5 or hCG+7, since the ERA checks the endometrium at the moment of implantation. This way, if you have a receptive result at P+5, you will transfer a blastocyst at P+5 or a day-3 embryo two days earlier, i.e. at P+3.

Interpretation of the results

Receptive: The gene expression profile is concordant with a receptive endometrium. The recommendation is to perform a blastocyst(s) transfer following the same protocol and timings utilized during the ERA test.

Late Receptive: The gene expression profile is concordant with an endometrium at the end of the receptive stage. The recommendation is to administer progesterone (HRT) or rest (natural cycle) for 12 hours less relative to when the biopsy was taken before performing a blastocyst(s) transfer.

Pre-receptive: The gene expression profile is concordant with an endometrium that has not reached yet the receptive stage. This could be due to a displacement of the window of implantation. In some cases, a new endometrial biopsy may be required to validate the predicted WOI.

Post-receptive: The gene expression profile is concordant with an endometrium that has already passed the receptive stage. This could be due to a displacement of the window of implantation. To validate the predicted WOI, the analysis of a subsequent biopsy on the recommended day is needed.

Proliferative: The gene expression profile is concordant with an endometrium that has not been exposed to progesterone or has not answered to it. It is recommended to contact Igenomix to evaluate the protocol in which the endometrial biopsy was performed.

* In approximately 3.3% of the samples received, a diagnosis cannot be obtained, this is due to obtaining a non-informative profile or the low quantity/quality of genetic material obtained.

* Following the recommendations of the ERA report does not guarantee implantation. Implantation failures may be caused by other factors.

We follow strict quality criteria ensuring that the RNA integrity and quantity are adequate avoiding potential artefactual results which could negatively affect the clinical outcome of your patients.

Invalid RNA. In transcriptomics analysis (whatever the technique) proper RNA integrity is required to ensure reliability of the result. In cases in which the RNA is highly degraded, the obtained gene expression profile wouldn't be trustable. This occurs in approximately 1.2% of samples received. In these cases, it is necessary to evaluate a new endometrial biopsy (the analysis won't be charged). Possible causes: sample size too large, contamination, and/or high temperature ($\geq 35^{\circ}\text{C}$) during shipment.

Insufficient RNA. Although with NGS the minimum quantity of RNA necessary to proceed with the analysis is very low, sometimes a low RNA concentration can lead to an inaccurate result. Our strict control systems allow us to identify the reliability of the obtained result. In approximately 1.5% of received samples it is not possible to determine an accurate gene expression profile because there is not enough genetic material. In these cases, it is necessary to evaluate a new endometrial biopsy (the analysis won't be charged). Possible causes: low quantity of proper tissue.

Non-Informative. This result is obtained when the profile analyzed does not match the control gene expression profiles present in the ERA predictor. In these cases, our team will contact you to evaluate the protocol in which the endometrial biopsy was performed. It just happens in $< 0.7\%$ of analyzed samples and in $> 95\%$ of cases, it is related to the sample itself, not the endometrium, since with a new biopsy (the analysis won't be charged) it is possible to obtain a valid result.

In any of these cases our ERA team will support and guide you, ensuring that we can find a valid result for your patient, based on quality and reliability.

ERA Example Report

The aim of this test is to provide physicians with an objective molecular assessment of the patient’s endometrial receptivity.

This test must be prescribed and interpreted by the physician who will perform the subsequent embryo transfer.



PART OF VITROLIFE GROUP


ERA (ENDOMETRIAL RECEPTIVITY ANALYSIS)

Patient information	Sample information	Clinic information
Unique pat id.:	Date received:	Clinic:
Sample type:	Report Date:	Clinician:
Patient name:	Progesterone*:	No. biopsy:
Patient DOB:	Measure date:	
	First intake of P4:	
	Date of biopsy:	
	Cycle type:	

TEST RESULTS:

RECEPTIVE: LATE RECEPTIVE

Recommendation#: The personalized embryo transfer (pET) of a blastocyst/s should be performed with 108 ± 3 hours of progesterone administration (12 hours earlier than the time at which this endometrial biopsy was performed). A new endometrial biopsy is not required. **



INTERPRETATION OF YOUR RESULT#:

The gene expression profile shows similarity to a late receptive stage. Blastocyst/s transfer is recommended with 108 ± 3 hours of progesterone administration (12 hours earlier than the time at which this endometrial biopsy was performed). Administration of progesterone can be delayed by 12 hours or the blastocyst transfer can be advanced by 12 hours relative to the timing used in the protocol for this endometrial biopsy.

For a day-3 embryo/s, the transfer should be performed two days earlier than indicated in the recommendation for blastocyst transfer above.

* Basal endogenous progesterone level prior to the first exogenous progesterone intake OR LH peak/hCG administration: Lower than 1 ng/ml. Date of measurement: 11/07/23.

** This recommendation is only applicable to the same type of cycle treatment as the one used for this endometrial biopsy and if the endogenous progesterone measured prior to the first progesterone intake is <1ng/ml.

TEST DESCRIPTION:

ERA (Endometrial Receptivity Analysis) is a molecular tool used to determine if the endometrium (the mucous membrane lining the womb) exhibits a receptive profile after 5 days of progesterone exposure, the time at which the endometrium is typically ready for embryo implantation. This molecular diagnosis method is based on measuring the gene expression profile of endometrial tissue. Therefore, ERA helps to determine when the endometrium presents the ideal condition for embryo implantation, increasing the possibility of a successful in vitro fertilization treatment.

COMMENTS




IGENOMIX SPAIN LAB, S.L.U. / C/ Nardo Monturrol nº11, Edificio Europark B, Parque Tecnológico, ES-46080 PATERNAL, Valencia, Tel: +34 963 905 310

#The marked sections are not within the scope of the ENAC accreditation.



MHE-00016862 1 1 3 2024

SPA_L_L_L_ERA_013_EN v3.1

Support: +34 963905310

Lab CLIA No.: 9502140587

In order to obtain a pET recommendation expressed in hours, we need the date and time of the endometrial biopsy and one of the following (depending on the cycle type):

- Date and time of the first P4 intake (HRT cycle)
- Date and time for hCG injection, LH surge or ovulation (Natural cycles)

The ERA report will indicate the optimum time to perform personalized embryo transfer (pET), or when to perform a new ERA biopsy (as appropriate).


* Following ERA report recommendations does not guarantee implantation. Failed implantation may be caused by other factors.

Reproducibility of the results

The ERA result has been **proven to be reproducible for at least** 36 months, provided the following:

- **Endometrial preparation protocol** must be exactly replicated for biopsy and transfer cycles.
- **Endometrial thickness** must be within the same range from one of the following three: **<6mm, 6-12mm, >12mm**; in both, biopsy and transfer cycles.
- **Changes in the BMI might be accompanied by a shift in the window of implantation.** The ERA test might need to be repeated after significant BMI changes (changing from > 30 to < 30) to ensure accuracy of the results.
- **Intervention at the uterine level** may affect the WOI. After this type of intervention, it should be evaluated if a new ERA needs to be performed. Indeed, if your patient requires any **intervention in the uterus** prior the embryo transfer, the ERA test should be done after this procedure.
- **Endogenous progesterone** properly controlled in biopsy and transfer cycles. **It must be < 1 ng/ml** within the 24 hours prior the first progesterone intake (HRT cycles) or at LH+0/hCG+0 (Natural cycles).

ERA decision tree



Relevant references

- Barbakadze T, Shervashidze M, Charkviani T, Zhorzholadze T, Kbilashvili T, Gabadze M et al. Assessment of the Role of Endometrial Receptivity Analysis in Enhancing Assisted Reproductive Technology Outcomes for Advanced-Age Patients. *Cureus*. **2024**; 16(6):e62949.
- Imoto S, Funabiki M, Nakamura Y, Taguchi S. Endometrial Receptivity Array (ERA) Test in a 32-Year-Old Female With Refractory Infertility: A Case Report. *Cureus*. **2024**; 16(3):e55703.
- Jia Y, Huang Y, Ai ZH, Dong YJ, Guo YH, Yang Y et al. Exploring the effectiveness of endometrial receptivity array and immune profiling in patients with multiple implantation failure : A retrospective cohort study based on propensity score matching. *J Reprod Immunol*. **2024**; 163:104218.
- Khan M, More A, Bawaskar PA, Kalbande A, Nair N. A Case Report on Endometrial Receptivity Array Test for Infertile Patient to Enhance Reproductive Outcomes. *Cureus*. **2024**; 16(2):e55059.
- Glujovsky D, Lattes K, Miguens M, Pesce R, Ciapponi A. Personalized embryo transfer guided by endometrial receptivity analysis: a systematic review with meta-analysis. *Hum Reprod*. **2023**; 38(7):1305-1317.
- He Y, Tang R, Yu H, Mu H, Jin H, Dong J, Wang W, Wang L, Chen S, Wang X. Comparative effectiveness and safety of 36 therapies or interventions for pregnancy outcomes with recurrent implantation failure: a systematic review and network meta-analysis. *J Assist Reprod Genet*. **2023**; 40(10):2343-2356.
- Luján-Irastorza JE. Assessing endometrial receptivity after recurrent implantation failure in euploid embryo transfer: a retrospective study in private clinic. *The Journal of Reproduction*. **2023**.
- Jia Y, Dong YJ, Sha YL, Cai SC, Diao LH, Qiu Z, Guo YH, Huang Y, Ye HX, Liu S. Effectiveness comparison between endometrial receptivity array, immune profiling and the combination in treating patients with multiple implantation failure. *Am J Reprod Immunol*. **2022**; 87(3):e13513.
- Jia Y, Sha Y, Qiu Z, Guo Y, Tan A, Huang Y. et al. Comparison of the Effectiveness of Endometrial Receptivity Analysis (ERA) to Guide Personalized Embryo Transfer with Conventional Frozen Embryo Transfer in 281 Chinese Women with Recurrent Implantation Failure. *Med Sci Monit*. **2022**; 28:e935634.
- Liu Z, Liu X, Wang M, Zhao H, He S, Lai S, Qu Q et al. The Clinical Efficacy of Personalized Embryo Transfer Guided by the Endometrial Receptivity Array/Analysis on IVF/ICSI Outcomes: A Systematic Review and Meta-Analysis. *Front Physiol*. **2022**; 13:841437.
- Rose B. Identifying women with a narrow window of embryo implantation using the endometrial receptivity assay. *Internat. Journal of Clinical Obs and Gyn*. **2022**; 6(3):52-54.
- Barrenetxea G, Romero I, Celis R, Abio A, Bilbao M, Barrenetxea J. Correlation between plasmatic progesterone, endometrial receptivity genetic assay and implantation rates in frozen-thawed transferred euploid embryos. A multivariate analysis. *Eur J Obstet Gynecol Reprod Biol*. **2021**; 263:192-197.
- Bellver, J., Marín, C., Lathi, R.B. et al. Obesity affects Endometrial Receptivity by displacing the Window of Implantation. *Reprod. Sci*. **2021**; 1-10.

- Kasahara Y, Hashimoto T, Yokomizo R, Takeshige Y, Yoshinaga K, Toya M et al. Evaluation of pregnancy outcomes of vitrified-warmen blastocyst transfer before and after Endometrial Receptivity Analysis in identical patients with Recurrent Implantation Failure. *Fertility & Reproduction*. **2020**; 3(2):35-41.
- Simón C, Gómez C, Cabanillas S, Vladimirov I, Castillón G, Giles J et al. A 5-year multicentre randomized controlled trial comparing personalized, frozen and fresh blastocyst transfer in IVF. *Reproductive BioMedicine Online* **2020**; 41(3):402-415.
- Hromadová L, Tokareva I, Veselá K, Trávník P, Veselý J. Endometrial Receptivity Analysis - a tool to increase an implantation rate in assisted reproduction. *Ceska Gynekol*. **2019**; 84(3): 177-183.
- Ota T, Funabiki M, Tada Y, Karita M, Hayashi T, Maeda K et al. The Reproductive Outcomes for the Infertile Patients with Recurrent Implantation Failures May Be Improved by Endometrial Receptivity Array Test. *Journal of Medical Cases*. **2019**;10(5):138-140.
- Patel JA, Patel AJ, Banker JM, Shah SI, Banker MR. Personalized Embryo Transfer Helps in Improving In vitro Fertilization/ICSI Outcomes in Patients with Recurrent Implantation Failure. *J Hum Reprod Sci*. **2019**; 12(1):59-66.
- Simrandeep K, Padmaja N. Why results of endometrial receptivity assay testing should not be discounted in recurrent implantation failure? *The Onco Fertility Journal*. **2019**; 2(1):46-49.
- Carranza F, González-Ravina A, Blasco V, Fernández-Sánchez M. Different Endometrial Receptivity in Each Hemiterus of a Woman With Uterus Didelphys and Previous Failed Embryo Transfers. *J Hum Reprod Sci*. **2018**;11(3):297-299.
- Clemente-Ciscar M, Ruiz-Alonso M, Blesa D, Jimenez-Almazan J, Bahceci M, Banker M et al. Endometrial receptivity analysis (ERA) using a next generation sequencing (NGS) predictor improves reproductive outcome in recurrent implantation failure (RIF) patients when compared to ERA arrays. *Hum Reprod*. **2018**; 33(Supp1):8-8.
- Findikli N, Gultomruk M, Boynukalin K, Kavrut M, Oral E, Bahceci M. Combinatorial use of Endometrial Receptivity Array (ERA) and PGT-A can improve the clinical outcome in cases with previous ART failures. *Hum Reprod*. **2018**; 33(Supp1):84-85.
- Mahajan N, Kaur S, Ruiz-Alonso M. Window of implantation is significantly displaced in patients with adenomyosis with previousimplantation failure as determined by endometrial receptivity assay. *Journal of human reproductive sciences*. **2018**; 11(4):353.
- Pasternak M, Schattman G, Rosenwaks Z. Pregnancy outcomes in patients undergoing embryo transfer in cycle following endometrial Receptivity assay. *Fertil Steril*. **2018**; 110(4):e243-244.
- Stankewicz T, Valbuena D, Ruiz-Alonso M. Inter-cycle consistency versus test compliance in endometrial receptivity analysis test. *J Assist Reprod Genet*. **2018**; 35(7):1307-1308.
- Taguchi S, Funabiki M, Hayashi T, Tada Y, Iwaki Y, Karita M et al. The implantation rate of Japanese infertile patients with repeated implantation failure can be improved by endometrial Receptivity array (ERA) test: A randomized controlled trial. *Fertil Steril*. **2018**; 110(4):e90.

- Comstock IA, Diaz-Gimeno P, Cabanillas S, Bellver J, Sebastian-Leon P, Shah M et al. Does an increased body mass index affect endometrial gene expression patterns in infertile patients? A functional genomics analysis. *Fertil Steril*. **2017** Mar;107(3):740-748.e2.
- Díaz-Gimeno P, Ruiz-Alonso M, Sebastian-Leon P, Pellicer A, Valbuena D, Simón C. Window of implantation transcriptomic stratification reveals different endometrial subsignatures associated with live birth and biochemical pregnancy. *Fertil Steril*. **2017**;108(4):703-710.e3
- Hashimoto T, Koizumi M, Doshida M, Toya M, Sagara E, Oka N et al. Efficacy of the endometrial Receptivity Array for repeated implantation failure in Japan: A retrospective, two-centers study. *Reprod Med Biol*. **2017**; 16(3):290-296.
- Valbuena D, Ruiz-Alonso M, Marin C, Soria J, Simon C, Garcia Velasco J. A. Endometrial thickness does not predict endometrial receptivity. In *HUMAN REPRODUCTION* **2016** (ESHRE); 31:255-256.
- Mahajan N. Endometrial receptivity array: Clinical application. *J Hum Reprod Sci*. **2015**; 8(3):121-9.
- Cruz F, Bellver J. Live birth after embryo transfer in an unresponsive thin endometrium. *Gynecol Endocrinol*. **2014**;30(7):481-4.
- Ruiz-Alonso M, Galindo N, Pellicer A, Simón C. What a difference two days make: "personalized" embryo transfer (pET) paradigm: a case report and pilot study. *Hum Reprod*. **2014**; 29(6):1244-7.
- Díaz-Gimeno P, Ruiz-Alonso M, Blesa D, Bosch N, Martínez-Conejero JA, Alamá P et al. The accuracy and reproducibility of the endometrial Receptivity array is superior to histology as a diagnostic method for endometrial Receptivity. *Fertil Steril*. **2013**; 99(2):508-17.
- Ruiz-Alonso M, Blesa D, Díaz-Gimeno P, Gómez E, Fernández-Sánchez M, Carranza F et al. The endometrial Receptivity array for diagnosis and personalized embryo transfer as a treatment for patients with repeated implantation failure. *Fertil Steril*. **2013**; 100(3):818-24.
- Díaz-Gimeno P, Horcajadas JA, Martínez-Conejero JA, Esteban FJ, Alamá P, Pellicer A, Simón C. A genomic diagnostic tool for human endometrial Receptivity based on the transcriptomic signature. *Fertil Steril*. **2011**; 95(1):50-60, 60.e1-15.

*You can check updated references in our website.

EMMA

Endometrial Microbiome Metagenomic Analysis

Rationale

The Human Microbiome Project (HMP) has highlighted **the importance of different microorganisms and their genomes in human health and disease** (Human Microbiome Project Consortium, 2012).

Identification of dysbiotic or pathogenic microbiomes may be key to improving clinical outcomes in various areas of medicine.

Previous research **identified the existence of an endometrial microbiome** and demonstrated that dysbiosis of the uterine cavity is associated with poor reproductive outcomes in assisted reproductive treatment patients (Moreno et al. Am J Obstet Gynecol, 2016). Recent publication has suggested that what may really interfere with fertility is the presence of pathogens in the uterine cavity, since the absence of bacteria, including *Lactobacillus*, do not impede implantation (Moreno et al. Microbiome, 2022).

According to the mentioned researches, EMMA (Endometrial Microbiome Metagenomic Analysis) could determine if the uterine microbial environment is optimal for embryo implantation. EMMA provides information about the endometrial bacterial composition, including potentially pathogenic bacteria related to chronic endometritis (CE) that can be specifically investigated in ALICE.

Indications for EMMA

The impact of the endometrial microbiome in patients with Repeated Implantation Failure (RIF) has been demonstrated (Moreno et al. Am J Obstet Gynecol, 2016). Therefore, EMMA can be especially useful in patients with recurrent implantation failure or repeated miscarriage. ALICE may also be beneficial for patients with a history of RPL and/or RIF, because CE has been linked to these adverse outcomes. EMMA includes ALICE and thus can also be beneficial for patients with a history of RPL.

Methodology

EMMA is a molecular test that provides microbiota information in endometrial tissue by analyzing a customized panel of bacteria including information about *Lactobacillus* genus, the 4 most common *Lactobacillus* species in the female reproductive tract (*L. jensenii*, *L. iners*, *L. gasseri* and *L. crispatus*) and potentially pathogenic bacteria of the reproductive tract (some of them related to chronic endometritis). This method is **based on detecting bacterial DNA through Real-Time PCR, which translates into different profiles that have been linked to the success of pregnancy. DNA extraction followed by microorganism-specific amplification** enables the quantification of targeted bacteria present in a sample.

A single endometrial sample contains both endometrial and bacterial cells. These can be analyzed to predict both endometrial receptivity (using ERA test) and endometrial microbiome. **EMMA thus provides a microbiological view of the endometrium, to improve clinical management of patients.**

EMMA Example Report

The EMMA report shows 3 tables with the reference ranges and the values obtained for each bacteria of the panel through the analysis of an endometrial sample:



Igenomix®
PART OF VITROLIFE GROUP™

ENDOMETRIAL MICROBIOME METAGENOMIC ANALYSIS (EMMA)

Patient information	Sample information	Clinic information
Unique pat id:	Date received:	Clinic:
Patient name:	Report date/time:	Clinician:
Patient DOB:	Sample type:	
Allergy to antibiotics:	Cycle type:	
	Cycle day:	
	No. Biopsy:	
	Date of biopsy:	

RESULTS OF EMMA TEST:

LACTOBACILLUS		
BACTERIA	RESULT	OPTIMAL RESULT
<i>Lactobacillus spp</i>	Detected	At least one species detected
<i>Lactobacillus crispatus</i>	Not detected	
<i>Lactobacillus gasseri</i>	Not detected	
<i>Lactobacillus iners</i>	Detected	
<i>Lactobacillus jensenii</i>	Not detected	

BACTERIA OF THE REPRODUCTIVE TRACT			
BACTERIA	RESULT	VALUE	REFERENCE RANGE
<i>Actinomyces israelii</i>	Not detected	N/A	Absent
<i>Atopobium vaginae</i>	Not detected	N/A	(0 - 3.58)
<i>Bacteroides fragilis</i>	Not detected	N/A	(0 - 3.57)
<i>Bifidobacterium spp</i> †	Not detected	N/A	(0 - 4.22)
<i>Clostridium sordellii</i>	Not detected	N/A	Absent
<i>Fusobacterium nucleatum</i>	Not detected	N/A	Absent
<i>Gardnerella vaginalis</i>	Detected	3.81*	(0 - 3.80)
<i>Haemophilus ducreyi</i>	Not detected	N/A	Absent
<i>Mycobacterium tuberculosis</i>	Not detected	N/A	Absent
<i>Mobiluncus spp</i>	Not detected	N/A	(0 - 3.57)
<i>Peptostreptococcus anaerobius</i>	Not detected	N/A	(0 - 3.57)
<i>Porphyromonas asaccharolytica</i>	Not detected	N/A	(0 - 3.57)
<i>Prevotella bivia</i>	Not detected	N/A	(0 - 3.57)
<i>Prevotella disiens</i>	Not detected	N/A	(0 - 3.57)
<i>Sneathia spp</i>	Not detected	N/A	(0 - 3.57)
<i>Treponema pallidum</i>	Not detected	N/A	Absent

RESULTS OF ALICE TEST:

BACTERIA RELATED TO CHRONIC ENDOMETRITIS			
BACTERIA	RESULT	VALUE	REFERENCE RANGE
<i>Chlamydia trachomatis</i>	Not detected	N/A	Absent
<i>Enterococcus faecalis</i>	Not detected	N/A	(0 - 3.57)
<i>Escherichia coli</i>	Not detected	N/A	(0 - 3.57)
<i>Klebsiella pneumoniae</i>	Not detected	N/A	(0 - 3.57)
<i>Mycoplasma genitalium</i>	Not detected	N/A	(0 - 3.57)
<i>Mycoplasma hominis</i>	Not detected	N/A	(0 - 3.57)
<i>Neisseria gonorrhoeae</i>	Not detected	N/A	Absent
<i>Staphylococcus aureus</i>	Not detected	N/A	(0 - 3.57)
<i>Streptococcus agalactiae</i> group B/ <i>Streptococcus viridans</i>	Not detected	N/A	(0 - 3.57)
<i>Ureaplasma urealyticum</i>	Not detected	N/A	(0 - 3.57)

†Bifidobacterium spp, when detected without other bacteria, could be displaced from its niche using probiotics.
*Values out of reference range.

RECOMMENDATION

The suggested treatment for the bacteria which DNA has been detected would be Metronidazole 500 mg/12h for 7 days orally, according to the standard Microbiology Guides (4,5). Subsequently, to recolonize the reproductive tract, it is suggested to use probiotics composed exclusively of Lactobacillus strains (preferably vaginal) following the manufacturer's instructions regarding dose and duration.

The analysis of a new biopsy is also recommended after treatment. The new sample must be taken following the standard test protocol.

Note: the numbers in brackets in the text of the report refer to scientific publications, which are listed at the end of the report.

The **reference ranges** for all bacteria included in the EMMA test have been calculated analyzing samples from women with a live birth that belong to a clinical study which led to the scientific publication *Moreno et al, Microbiome 2022*.

The EMMA test results include information about:

1) **Table 1:** detection of DNA from *Lactobacillus*.

<i>LACTOBACILLUS</i>		
BACTERIA	RESULT	OPTIMAL RESULT
<i>Lactobacillus spp</i>	Detected	At least one species detected
<i>Lactobacillus crispatus</i>	Not detected	
<i>Lactobacillus gasseri</i>	Not detected	
<i>Lactobacillus iners</i>	Detected	
<i>Lactobacillus jensenii</i>	Not detected	

In cases in which there are no pathogens detected out of their reference range, **if at least one of the *Lactobacillus* species or *Lactobacillus spp* are detected, this is considered a normal result.**

2) **Table 2: potentially pathogenic bacteria from the reproductive tract** with clinical relevance and **not related to chronic endometritis**:

BACTERIA OF THE REPRODUCTIVE TRACT			
BACTERIA	RESULT	VALUE	REFERENCE RANGE
<i>Actinomyces israelii</i>	Not detected	N/A	Absent
<i>Atopobium vaginae</i>	Not detected	N/A	(0 - 3.58)
<i>Bacteroides fragilis</i>	Not detected	N/A	(0 - 3.57)
<i>Bifidobacterium spp</i> †	Not detected	N/A	(0 - 4.22)
<i>Clostridium sordellii</i>	Not detected	N/A	Absent
<i>Fusobacterium nucleatum</i>	Not detected	N/A	Absent
<i>Gardnerella vaginalis</i>	Detected	3.81*	(0 - 3.80)
<i>Haemophilus ducreyi</i>	Not detected	N/A	Absent
<i>Mycobacterium tuberculosis</i>	Not detected	N/A	Absent
<i>Mobiluncus spp</i>	Not detected	N/A	(0 - 3.57)
<i>Peptostreptococcus anaerobius</i>	Not detected	N/A	(0 - 3.57)
<i>Porphyromonas asaccharolytica</i>	Not detected	N/A	(0 - 3.57)
<i>Prevotella bivia</i>	Not detected	N/A	(0 - 3.57)
<i>Prevotella disiens</i>	Not detected	N/A	(0 - 3.57)
<i>Sneathia spp</i>	Not detected	N/A	(0 - 3.57)
<i>Treponema pallidum</i>	Not detected	N/A	Absent

Values of bacteria **out of the reference range** are identified in bold, highlighted and with an asterisk.

Note: If any of the pathogens associated with Sexually Transmitted Infections (*Haemophilus ducreyi* and/or *Treponema pallidum*) are out of the reference range, an additional confirmatory test will be recommended. Infections caused by these bacteria require mandatory notification to the local Health Authorities in different countries. In the case that these pathogens are identified, it is the doctor's responsibility to declare these infections.

3) **Table 3:** potentially pathogenic bacteria that are **most commonly associated with chronic endometritis (ALICE test)**

BACTERIA RELATED TO CHRONIC ENDOMETRITIS			
BACTERIA	RESULT	VALUE	REFERENCE RANGE
<i>Chlamydia trachomatis</i>	Not detected	N/A	Absent
<i>Enterococcus faecalis</i>	Not detected	N/A	(0 - 3.57)
<i>Escherichia coli</i>	Not detected	N/A	(0 - 3.57)
<i>Klebsiella pneumoniae</i>	Not detected	N/A	(0 - 3.57)
<i>Mycoplasma genitalium</i>	Not detected	N/A	(0 - 3.57)
<i>Mycoplasma hominis</i>	Not detected	N/A	(0 - 3.57)
<i>Neisseria gonorrhoeae</i>	Not detected	N/A	Absent
<i>Staphylococcus aureus</i>	Not detected	N/A	(0 - 3.57)
<i>Streptococcus agalactiae</i> group B/ <i>Streptococcus</i> <i>viridans</i>	Detected	3.81*	(0 - 3.57)
<i>Ureaplasma urealyticum</i>	Not detected	N/A	(0 - 3.57)

***Values out of reference range.**

Values of bacteria **out of the reference range** are identified in bold, highlighted and with an asterisk.

Note: If any of the pathogens associated with Sexually Transmitted Infections (*Chlamydia trachomatis* and/or *Neisseria gonorrhoeae*) are out of the reference range, an additional confirmatory test will be recommended. Infections caused by these bacteria require mandatory notification to the local Health Authorities in different countries. In the case that these pathogens are identified, it is the doctor's responsibility to declare these infections.

The **EMMA report also includes a recommendation** (if necessary) to achieve values that are within the established reference range for all bacteria included in the panel. In these cases, the antibiotic recommendation given in the report is based on the Microbiological guidelines.

The result obtained by this test and the suggested treatment recommendation, constitute information that must be assessed by a physician in the setting of a clinical consultation. It is the medical professional who must consider the possible prescription of an antibiotic and/or probiotic treatment in conjunction with the available clinical findings of each patient. Thus, patients should not take any antibiotic without previous physician consultation.

Furthermore, a section with **interpretation of all results** obtained is also included.

INTERPRETATION OF EMMA RESULTS

DNA from reproductive tract potentially pathogenic bacteria, not related to chronic endometritis, has been detected out of reference range. Igenomix recommends normalizing these values before performing an embryo transfer to improve the chances of a successful pregnancy according to scientific evidence (1,2,3).

Both, the result obtained by this test and the suggested treatment recommendation, constitute information that must be assessed by a physician in the setting of a clinical consultation. It is the medical professional who must consider the possible prescription of an antibiotic and/or probiotic treatment in conjunction with the available clinical findings of each patient. In the case of prescribed treatment, it is also recommended to analyze a new biopsy after its completion to confirm normalized values of potentially pathogenic bacteria. The new sample must be taken following the standard test protocol.

Lactobacillus DNA has been detected in the endometrial sample. Lactobacillus is the predominant bacteria in the female reproductive tract during reproductive age. It is not necessary to have different Lactobacillus strains, but it is recommended to have at least one of them to protect the endometrium from pathogens colonization. Keep in mind that the use of antibiotics could affect the current Lactobacillus population causing its decline or even its disappearance.

In a very low percentage of cases some of the following results may be obtained:

- Inconclusive: it is not possible to determine the bacterial profile of the sample.
- Invalid sample: the sample does not meet the minimum quality parameters required to obtain a reliable result. This may be due to a lack of quantity or quality of the genetic material obtained.


In both cases a new biopsy will be required following the indications of the test.

Benefits of molecular analysis of the microbiota vs microbial culture

Microbial culture is the current gold-standard method for assessment of bacterial populations and infection. However, it has been demonstrated that between 20% and 60% of bacteria cannot be cultured. Molecular assessment of the microbiome allows detection of culturable and non-culturable bacteria present in a sample.

	CULTURE	MOLECULAR
BASED ON	The identification of culturable endometrial pathogens	The use of Real-Time PCR to detect all bacteria (including difficult-to-culture)
OBJECTIVE RESULTS	YES	YES
SPECIFIC (TARGETED AB TREAT.)	YES	YES
DETECTS NON-CULTURABLE BACT	NO	YES
SHORT TURNAROUND TIME	NO	YES

EMMA decision tree



¹ Optimal: no pathogens detected and *Lactobacillus* detected

* After treatment, it must be decided if going directly to the embryo transfer or repeating the EMMA test to ensure the clearance of potentially pathogenic bacteria.

References

- Iwami N, Komiya S, Asada Y, Tatsumi K, Habara T, Kuramoto T, et al. Shortening time to pregnancy in infertile women by personalizing treatment of microbial imbalance through Emma & Alice: A multicenter prospective study. *Reprod Med Biol.* **2025**; 24(1):e12634.
- Iwami N, Kawamata M, Ozawa N, Yamamoto T, Watanabe E, Mizuuchi M, et al. Therapeutic intervention based on gene sequencing analysis of microbial 16S ribosomal RNA of the intrauterine microbiome improves pregnancy outcomes in IVF patients: a prospective cohort study. *J Assist Reprod Genet.* **2023**; 40(1):125-135.
- Moreno I, Garcia-Grau I, Perez-Villaroya D, Gonzalez-Monfort M, Bahçeci M, Barrionuevo MJ, et al. Endometrial microbiota composition is associated with reproductive outcome in fertile patients. *Microbiome.* **2022**; 10(1):1.
- Moreno I, Garcia-Grau I, Bau D, Perez-Villaroya D, Gonzalez-Monfort M, Vilella F, et al. The first glimpse of the endometrial microbiota in early pregnancy. *American Journal of Obstetrics and Gynecology.* **2020**; 222(4):296-305.
- Garcia-Grau I, Perez-Villaroya D, Bau D, Gonzalez-Monfort M, Vilella F, Moreno I, Simón C. Taxonomical and functional assessment of the endometrial microbiota in a context of recurrent reproductive failure: a case report. *Pathogens* **2019**; 8:205.
- Moreno I and Simon C. Screening the Uterine Microbiome Prior to Embryo Transfer. In: *How to Prepare the Endometrium to Maximize Implantation Rates and IVF Success* Edited by G. Kovacs & L. Salamonsen; 2019. Chapter 6 (pp. 54-64). Cambridge: Cambridge University Press.
- Franasiak JM, Moreno I, Simon C. Microbiome in Embryonic Implantation and Implantation Failure. *Recurrent Implantation Failure, Etiologies and Clinical Management.* **2018**; 11:175 - 195.
- Garcia-Grau I, Simon C, Moreno I. Uterine microbiome-low biomass and high expectations†. *Biol Reprod.* **2019**; 101(6):1102-1114.
- Moreno I and Simon C. Relevance of assessing the uterine microbiota in infertility. *Fertility and Sterility.* **2018**; 110(3):337-343.

- Moreno I, Garcia-Grau I, Simon C. Microbiota and Pathogen Screening in the Female Reproductive Tract. In: Encyclopedia of Reproduction. 2018; Chapter 9, vol. 4, pp. 36 - 44. Academic Press: Elsevier.
- Simon C, Moreno I. Deciphering the effect of reproductive tract microbiota on human reproduction. Reproductive Medicine and Biology. **2018**; 18(1): 40 - 50.
- Moreno I, Franasiak JM. Endometrial microbiota - new player in town. Fertility and Sterility. **2017**; 108, pp. 32 - 39.
- Moreno I, Codoñer FM, Vilella F, Valbuena D, Martinez-Blanch JF, Jimenez-Almazan J, et al. Evidence that the endometrial microbiota has an effect on implantation success or failure. Am J Obstet Gynecol. **2016**; 215:684-703.
- Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature **2012**; 486:207-14.

*You can check updated references in our website.

ALICE

Analysis of Infectious Chronic Endometritis



Rationale

A good example of pathology caused by an altered endometrial microbiota is chronic endometritis (CE). **CE is a persistent inflammation of the endometrial lining, caused by infection of the uterine cavity, mainly by bacterial pathogens.** Because it is usually asymptomatic and current classical diagnosis methods (histology, hysteroscopy and microbial culture) are unsatisfactory, CE is often overlooked, although it affects approximately 30% of infertile women, and prevalence in patients with Recurrent Implantation Failure (RIF) and Repeated Pregnancy Loss (RPL) may reach higher percentages.

A study carried out by Igenomix has demonstrated that molecular assessment of CE is a reliable diagnostic method compared to classical methods (Moreno et al. Am J Obstet Gynecol, 2018). **This new approach should improve detection of this often-undiagnosed endometrial pathology, by identifying specific microorganisms and enabling guided, personalized treatment.**

ALICE (Analysis of Infectious Chronic Endometritis), detects the most frequent bacteria that cause chronic endometritis. This test allows for the evaluation of the endometrium at the microbiological level, with the aim of improving the clinical management of patients with this silent disease.

Indications for ALICE

ALICE can be beneficial for patients with suspicious of CE or with a history of RPL and/or RIF, because CE has been linked to these adverse outcomes.

Methology

The ALICE test utilizes Real-Time PCR to provide a molecular screening of CE in endometrial tissue by analyzing the bacteria most commonly causing the disease (*Streptococcus agalactiae* (group B) & *Streptococcus viridans*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Mycoplasma hominis*, *Mycoplasma genitalium*, *Escherichia coli*, *Klebsiella pneumoniae*, *Ureaplasma urealyticum*, *Chlamydia trachomatis* and *Neisseria gonorrhoeae*). **The technology used for these purposes is based on DNA extraction followed by microorganism-specific amplification that enables the quantification of targeted bacteria present in a sample.** After receiving the endometrial biopsy and extracting the genetic material (DNA), sample minimum quality requirements are evaluated before testing.

A single endometrial sample contains both endometrial and bacterial cells. These can be analyzed using deep sequencing to predict endometrial receptivity and Real-Time PCR for the study of the aforementioned pathogens.

ALICE report example

The ALICE report shows a table with the reference ranges and the values obtained for each bacteria of the panel through the analysis of an endometrial sample:



ANALYSIS OF INFECTIOUS CHRONIC ENDOMETRITIS (ALICE)

Patient information	Sample information	Clinic information
Unique pat id:	Date received:	Clinic:
Patient name:	Report date/time:	Clinician:
Patient DOB:	Sample type:	
Allergy to antibiotics:	Cycle type:	
	Cycle day:	
	No. Biopsy:	
	Date of biopsy:	

RESULTS OF ALICE TEST:

BACTERIA RELATED TO CHRONIC ENDOMETRITIS			
BACTERIA	RESULT	VALUE	REFERENCE RANGE
<i>Chlamydia trachomatis</i>	Not detected	N/A	Absent
<i>Enterococcus faecalis</i>	Detected	3.62*	(0 - 3.57)
<i>Escherichia coli</i>	Not detected	N/A	(0 - 3.57)
<i>Klebsiella pneumoniae</i>	Not detected	N/A	(0 - 3.57)
<i>Mycoplasma genitalium</i>	Not detected	N/A	(0 - 3.57)
<i>Mycoplasma hominis</i>	Not detected	N/A	(0 - 3.57)
<i>Neisseria gonorrhoeae</i>	Not detected	N/A	Absent
<i>Staphylococcus aureus</i>	Not detected	N/A	(0 - 3.57)
<i>Streptococcus agalactiae</i> group B/ <i>Streptococcus viridans</i>	Not detected	N/A	(0 - 3.57)
<i>Ureaplasma urealyticum</i>	Not detected	N/A	(0 - 3.57)

*Values out of reference range.

RECOMMENDATION

The suggested treatment for the bacteria which DNA has been detected would be Amoxicillin 500mg/8h for 7 days orally, according to the standard Microbiology Guides (4,5). Subsequently, to recolonize the reproductive tract, it is suggested to use probiotics composed exclusively of Lactobacillus strains (preferably vaginal) following the manufacturer's instructions regarding dose and duration.

The analysis of a new biopsy is also recommended after treatment. The new sample must be taken following the standard test protocol.

Values of potentially pathogenic bacteria **out of the reference range** are identified in bold, highlighted and with an asterisk.

Note: If any of the **pathogens associated with Sexually Transmitted Infections (*Chlamydia trachomatis* and/or *Neisseria gonorrhoeae*)** are out of the reference range, an additional confirmatory test will be recommended. Infections caused by these bacteria require mandatory notification to the local Health Authorities in different **countries**. In the case that these pathogens are identified, it is the doctor's responsibility to declare these infections.

The ALICE report also includes a recommendation (if necessary) to achieve values that are within the established reference range for all bacteria included in the panel. In these cases, the antibiotic recommendation given in the report is based on the Microbiological guidelines.

The result obtained by this test and the suggested treatment recommendation, constitute information that must be assessed by a physician in the setting of a clinical consultation. It is the medical professional who must consider the possible prescription of an antibiotic and/or probiotic treatment in conjunction with the available clinical findings of each patient. Thus, patients should not take any antibiotic without previous physician consultation.

Furthermore, a section with interpretation of the result obtained is also included.

Example:

INTERPRETATION OF ALICE RESULTS

DNA from potentially pathogenic bacteria related to chronic endometritis has been detected out of reference range in the endometrial sample. Igenomix recommends normalizing these values before performing an embryo transfer to improve the chances of a successful pregnancy according to scientific evidence (1,2,3).

Both, the result obtained by this test and the suggested treatment recommendation, constitute information that must be assessed by a physician in the setting of a clinical consultation. It is the medical professional who must consider the possible prescription of an antibiotic and/or probiotic treatment in conjunction with the available clinical findings of each patient. In the case of prescribed treatment, it is also recommended to analyze a new biopsy after its completion to confirm normalized values of pathogens. The new sample must be taken following the standard test protocol.

Note: the numbers in brackets in the text of the report refer to scientific publications, which are listed at the end of the report.

In a very low percentage of cases, some of the following results may be obtained:

- Inconclusive: it is not possible to determine the bacterial profile of the sample.
- Invalid sample: the sample does not meet the minimum quality parameters required to obtain a reliable result. This may be due to a lack of quantity or quality of the genetic material obtained. A new biopsy is required following the indications of the test.

In both cases a new biopsy will be required following the indications of the test.

Benefits of molecular analysis of the microbiota vs histology, hysteroscopy and microbial culture

Current diagnosis of CE is traditionally based on histology, hysteroscopy and/or microbial culture. However, **these three classical methods provide inconclusive or misleading results in 80% of cases**. While histology usually underdiagnoses CE, hysteroscopy usually overdiagnoses the disease. These methods cannot accurately identify the pathogens causing the disease, and broad-spectrum antibiotics are often prescribed.

Microbial culture is able to isolate the causative pathogen; however, between 20% and 60% of bacteria cannot be cultured in standard laboratory conditions or are not usually assessed in clinical practice.

Molecular microbiology provides equivalent results to the combined results obtained by using histology, hysteroscopy and microbial culture (Moreno et al. Am J Obstet Gynecol, 2018).


	HISTOLOGY	HYSTEROSCOPY	CULTURE	MOLECULAR
BASED ON	The identification of CD138+ Plasma Cells in the endometrial stroma	The identification of stromal edema, focal or diffuse epithelial hyperemia, and/or the presence of micropolyps	The identification of culturable endometrial pathogens	The use of Real-Time PCR to detect all bacteria (including difficult-to-culture)
OBJECTIVE RESULTS	NO	NO	YES	YES
SPECIFIC (TARGETED AB TREAT.)	NO	NO	YES	YES
DETECTS NON-CULTURABLE BACT	NO	NO	NO	YES
SHORT TURNAROUND TIME	NO	YES	NO	YES



ALICE

Detects the bacteria
causing chronic
endometritis

ALICE decision tree



* After treatment, it must be decided if going directly to the embryo transfer or repeating the ALICE test to ensure the clearance of pathogens.



References

- Moreno I, Cicinelli E, Garcia-Grau I, Gonzalez M, Bau D, Vilella F, De Ziegler D, Resta L, Valbuena D, Simon C. The diagnosis of chronic endometritis in infertile asymptomatic women: a comparative study of histology, microbial cultures, hysteroscopy, and molecular microbiology. *Am J Obstet Gynecol.* **2018**; 218(6):602.e1-602.e16
- Moreno I, C. Simón. Microbiological diagnosis: the human endometrial microbiome—Endometritis. In: *The Endometrial Factor, A Reproductive Precision Medicine Approach*. Edited by Simón C and Giudice L. Taylor & Francis Group; **2017**. Chapter 5.
- Cicinelli E, Matteo M, Tinelli R, Lepera A, Alfonso R, Indraccolo U, Marocchella S, Greco P, Resta L. Prevalence of chronic endometritis in repeated unexplained implantation failure and the IVF success rate after antibiotic therapy. *Hum Reprod.* **2015**; 30(2):323-30.
- Cicinelli E, Matteo M, Tinelli R, Pinto V, Marinaccio M, Indraccolo U, De Ziegler D, Resta L. Chronic endometritis due to common bacteria is prevalent in women with recurrent miscarriage as confirmed by improved pregnancy outcome after antibiotic treatment. *Reprod Sci* **2014**; 21(5):640-7.

*You can check updated references in our website.

Endometrial Biopsy



Requirements for taking an endometrial biopsy

- Endometrial biopsy for ERA, EMMA, ALICE or EndomeTRIO tests should be taken following all this manual's indications.
- The endometrial biopsy can be taken in the gynaecologist consultant, without using anesthetic. **If a biopsy is going to be taken during a hysteroscopy, we recommend taking it at the beginning of the procedure**, before distending the uterine cavity and without antibiotic treatment before, during or after the procedure. The biopsy only can be taken if the hysteroscopy is observational, with no intervention performed.
- To perform the EMMA or ALICE tests (alone or with ERA test), antibiotic intake should be avoided at least the 7 days prior to taking the sample, during the procedure and until receiving the test results. In this way, the microbiome of the biopsy day will be representative of the patient's microbiome the day in which the test results are received. **Any drugs that may alter the patient's microbiota or immunological status should also be included in the test requisition form**, including all the data related to taking antibiotics during the month prior to the biopsy (active ingredient, route of administration, dose and duration of treatment).



Day of Endometrial Biopsy for ERA alone or coupled with EMMA/ALICE

In the case of an ERA test is requested (alone or coupled with other tests) the endometrial biopsy should be performed according to the indications described below:

- 1. The ERA diagnosis is valid for the type of cycle in which the test was performed,** and therefore the embryo must be transferred in the same type of cycle and the personalized window of implantation within which a 'Receptive' diagnosis was obtained. Therefore, the type of cycle for biopsy should match to the type of cycle planned for the embryo transfer.
- 2. Cycle type:** Hormone Replacement Therapy (P+5) or Natural cycle (hCG+7/LH+7/Ovulation+6) as explained as follows. Note: If Day-3 embryos are to be transferred, the biopsy should still be performed at P+5 or hCG+7/LH+7/Ovulation+6, since the ERA checks the endometrium at the moment of implantation. In this way, if you have a receptive result at P+5, you will transfer a blastocyst at P+5 or a Day-3 embryo two days earlier, i.e. at P+3.


2a) Hormone Replacement Therapy cycle (HRT): involves treatment with estrogen and progesterone to prepare the endometrium in a controlled manner, similar to a natural cycle for embryo transfer, using the routine protocol at the clinic or our standard protocol:

Patient starts estradiol therapy from the 1st or 2nd day of the menstrual cycle. Ultrasound assessment is performed 7 to 10 days later. Please note that we don't recommend the estradiol therapy to be longer than 17 days before the start of the progesterone intake.



Start progesterone (P4) intake when a trilaminar endometrium >6 mm is reached with a serum P4 <1 ng/ml (within 24 hours prior to starting exogenous P4), continuing with estradiol treatment. The day on which the P4 treatment starts is referred to as P+0, and the biopsy is taken on day P+5, after 5 full days (120 hours from the first intake to biopsy collection).

HRT Routine Protocol:



- In an HRT cycle it is very important to ensure that there is no ovulation, and therefore endogenous P4 level should always be measured within the 24 hours prior to the first P4 intake. The level should be <1 ng/ml, otherwise the recommendation is to cancel the cycle and start a new one. Failure to properly control for endogenous P4 may result in an endogenous P4 artifact that can affect the accuracy and reproducibility of the ERA results.
- **Personalized embryo transfer time (pET) will be based on the total exogenous progesterone exposure time** (the reference point will be day P+0).




2b) Natural cycle: For Natural Cycles we always need to have a reference date regarding ovulation timing, which could be one of the following three options:

- i. **hCG (recombinant or urinary) date:** hCG is administered according to routine parameters in a natural cycle (follicle size >17 mm). The day of the hCG administration is considered as hCG+0 and the biopsy will be taken 7 days later, at hCG+7 (168 hours after hCG triggering).
- ii. **LH surge date:** to properly detect the LH peak, the LH levels in urine or blood must be measured during several followed days (from day 9 in a regular cycle) obtaining at least one positive flanked by two negative results. The day of the LH surge is considered as LH+0 and the biopsy will be taken 7 days later, at LH+7.
- iii. **Ovulation date:** The sample can be also collected in a natural cycle, during secretory phase, because ovulation induces the production of estrogens and progesterone. The day of ovulation determined by ultrasound will be considered as Ov+0 and the biopsy will be collected 6 days later, at Ov+6.

In Natural cycles, progesterone supplementation can be administered, being then referred to as Modified Natural cycles. In these cycles the reference date for the pET recommendation still is the hCG/LH/Ovulation date. The progesterone supplementation can start from LH+1/hCG+1/Ov+0, at the moment in which it is usually done in the routine clinical practice of your center (never prior hCG triggering or LH surge). The progesterone supplementation protocol used in the ERA cycle should be replicated in the transfer cycle (i.e. if a patient starts progesterone supplementation at hCG+2 for the biopsy cycle, it should be started also at hCG+2 in the transfer cycle, independently of the result obtained).

Natural Routine Protocol:



To ensure that there is no endogenous progesterone escape by the time of hCG trigger/LH surge, the endogenous P4 level should always be measured at hCG+0/LH+0 and this should be <1ng/ml, otherwise the recommendation is to cancel the cycle and start a new one. Failure to properly control for endogenous P4 may result in an endogenous P4 artifact that can affect the accuracy and reproducibility of the ERA results.

The personalize embryo transfer (pET) will be based off hCG/LH/ovulation. Please note that if we do not have this information in Natural cycles, our recommendation is to cancel the analysis. The ERA test cannot be performed without this reference date since the result would not be reproducible.



Day of Endometrial Biopsy for EMMA and/or ALICE (without ERA)

For EMMA/ALICE tests the patient should **avoid antibiotics at least 7 days before biopsy collection, during the procedure, and after the procedure until results are received.**

The **endometrial biopsies for EMMA&ALICE tests must be always collected in the secretory phase** because this is the period of maximum stability of the reproductive tract microbiota due to the influence of estrogens and progesterone. **A sample taken outside the conditions indicated below, could give us a non-reliable result.**

If an EMMA or ALICE test is requested alone, the endometrial biopsy can be taken following the same protocol as for ERA. If ERA protocol is not followed, the biopsy must be taken as follows:

- a) HRT cycles:** the samples must be taken during the progesterone intake days (P+1 onwards), preferably on day P+5.
- b) Natural or Modified Natural cycle:** The biopsy must be taken between days 15 and 25 of the menstrual cycle if the patient has regular cycles (between 26 to 32 days).

For patients with non-regular cycles, we recommend performing an HRT cycle or monitoring ovulation. In this case, the biopsy can be taken on days:

- LH+2 to LH+12 (both inclusive)
- hCG+2 to hCG+12 (both inclusive)
- Ov+1 to Ov+11 (both inclusive)



- c) Oral Contraceptive Pills (OCPs):** only for OCPs with certain compositions. Please, confirm always with Igenomix before scheduling the biopsy. The biopsy must be taken between **days 14 to 21 of OCPs (days of active pills intake when the patient also takes the placebo pills), or on day 14 and onwards (if the patient doesn't take placebo pills neither have a rest, and is under continuous use).**

Day of endometrial biopsy: summary table

Cycle type	ERA	EMMA&ALICE	Comments
HRT	P+5 (120hrs)	P+1 Onwards	
Natural or Modified Natural	hCG+7 (168 hrs) LH+7 (168 hrs) Ov+6 (144 hrs)	hCG+2 to hCG+12 LH+2 to LH+12 Ov+1 to Ov+11 Cycle Days 15 to 25 (only for patients with regular cycles)	The times recommended for EMMA&ALICE apply to patients with regular cycles 26-32 days. Otherwise, we recommend performing an HRT cycle or to monitor ovulation. For each period, the first and last dates are included.
During OCPs	NO	14 - 21 (days of active intake pills if patient has also placebo pills) 14 onwards (continuous intake of active pills)	Not all OCPs will be suitable for EMMA/ALICE. We recommend pre-approving OCP prior to patient biopsy cycle. For each period, the first and last dates are included.

Day of endometrial biopsy: non-valid protocols

Cycle type	Cycle Day	ERA	EMMA&ALICE	Comments
Controlled ovarian stimulation	NA	NO	NO	Samples cannot be collected in a stimulated cycle as conditions cannot be replicated during the pET cycle. The microbiome is not representative because hormone levels are not comparable to a Natural or HRT cycle.
Biopsy during the follicular phase	NA	NO	NO	Samples must only be collected during the secretory phase to ensure microbiome stability.



Endometrial Biopsy protocol

A single endometrial biopsy is sufficient for an individual test or for EndomeTRIO (ERA, EMMA, and ALICE). Igenomix will supply a cryotube for each biopsy. The cryotube contains 1.5 ml of a transparent solution to preserve the genetic material.

- 1. Clean cervix with sterile, dry gauze** (avoid the use of betadine) and do not introduce fluid into the endometrium.
- 2. Label tube** with: patient name, DOB and date of biopsy.
- 3. The endometrial biopsy must be taken from the uterine fundus using a Pipelle or similar.** Please make sure that it is CE marked and inform us by email about its characteristics.
- 4. Collect at least 70mg of tissue** (corresponds to a cubic piece of tissue with sides of approximately 7 mm). The **sample volume must not exceed the white line marked on the cryotube (corresponding to 1/3 of the total cryotube volume; see picture below)**. For bigger amounts of tissue there will not be sufficient stabilizing in the cryotube (which will lead to genetic material degradation).





5. Ensure that the sample is made up of endometrial tissue, not solely blood or mucus. Excessive amounts of blood or mucus should also be avoided.

6. Avoid the contact of the sample with any solution other than the buffer in the tube (don't wash the sample).

7. After the biopsy has been performed, the sample should be transferred immediately to the supplied cryotube avoiding touching the tube with the Pipelle and shaking vigorously for at least 10 seconds (to ensure that the buffer penetrates the tissue and stabilizes the genetic material of the sample).

8. The cryotube containing the sample should be immediately transferred to a refrigerator (4-8°C /39-46°F) and stored there for at least 4 hours (do not place in the freezer before completing these 4 hours).

9. After refrigerating for at least 4 hours, samples may be sent to Igenomix at room temperature. If samples are going to be exposed to >35°C/95°F, we recommend shipping them with a cold gelpack. Deliveries at room temperature should never exceed 5 days.

10. Samples may also be kept in a refrigerator for up to 3 weeks or may be frozen at -20°C/-4°F (after the first 4 hours at 4-8°C/39-46°F) if not being sent to Igenomix straightaway. However, in the case of an EMMA, ALICE or EndomeTRIO test, as the microbiome can fluctuate over time, the recommendation is to process the sample as soon as possible after collection. We do not recommend delaying the shipment of samples for more than a week.



Logistics

Sample and documents:

- Read and complete properly the "Test Requisition Form" and "Informed Consent."
- Place the cryotube containing the biopsy inside the rigid plastic blister and close it. Place the rigid plastic blister inside the kit and place it in the plastic (courier) return bag (provided by Igenomix). Insert the receptacle inside the kit box and the box inside the return bag.
- Place the completed "Test Requisition Form" and "Informed Consent" inside the return bag.
- Depending on the geographic area, Courier documents and/or a UN3373 sticker may be required.
- Shipments at room temperature should not exceed 5 days in order to ensure the preservative action of the liquid in the cryotube. We recommend shipping the samples with a cold gelpack if outside temperatures exceed 35°C/95°F. For further details, please contact us.

Shipment:

- Please inform us by email about each shipment indicating the number of samples and their clinical or reference record number.
- You may use your usual courier, or alternatively ask us about our pick up service.

A complete view of the endometrial health

REQUESTED TEST		TESTS INCLUDED AND APPLICATION			
EndomeTRIO The endometrium matters	ENDOMETRIAL RECEPTIVITY ANALYSIS Expression of 248 genes to guide pET*	+	ENDOMETRIAL MICROBIOME ANALYSIS Lactobacilli and pathogenic bacteria of the reproductive tract Molecular detection of bacteria present to allow for more personalized treatment	+	CHRONIC ENDOMETRITIS Pathogenic bacteria related to CE Molecular detection of CE pathogens to allow for more personalized treatment
ERA® Endometrial Receptivity Analysis	ENDOMETRIAL RECEPTIVITY ANALYSIS Expression of 248 genes to guide pET*				
EMMA Endometrial Microbiome Metagenomic Analysis			ENDOMETRIAL MICROBIOME ANALYSIS Lactobacilli and pathogenic bacteria of the reproductive tract Molecular detection of bacteria present to allow for more personalized treatment	+	CHRONIC ENDOMETRITIS Pathogenic bacteria related to CE Molecular detection of CE pathogens to allow for more personalized treatment
ALICE Analysis of Infectious Chronic Endometritis					CHRONIC ENDOMETRITIS Pathogenic bacteria related to CE Molecular detection of CE pathogens to allow for more personalized treatment

*pET: personalized embryo transfer

List of abbreviations

ALICE	Analysis of Infectious Chronic Endometritis
BMI	Body Mass Index
CE	Chronic Endometritis
DNA	Deoxyribonucleic Acid
E₂	Estrogens
EMMA	Endometrial Microbiome Metagenomic Analysis
ERA	Endometrial Receptivity Analysis
hCG	Human Chorionic Gonadotropin
HMP	Human Microbiome Project
HRT	Hormone Replacement Therapy
LH	Luteinizing Hormone
NGS	Next Generation Sequencing
OCPs	Oral Contraceptive Pills
Ov	Ovulation
P₄	Progesterone
PCR	Polymerase Chain Reaction
pET	Personalized Embryo Transfer
RIF	Recurrent Implantation Failure
RNA	Ribonucleic Acid
RPL	Recurrent Pregnancy Loss
WOI	Window of Implantation

